Anti-PD-1 (Camrelizumab), Humanized Antibody

Anti-PD-1 (Camrelizumab), Humanized Antibodyis available at Gentaur for Next week Delivery.

Description: Camrelizumab (AiRuiKa™) is a humanized monoclonal IgG4 anti-PD-1 monoclonal antibody developed by Jiangsu Hengrui Medicine Co. Ltd for the treatment of various solid and hematological malignancies. Upon administration, the antibody blocks the binding of PD-1 to its ligands PD-L1 and PD-L2. This inhibits PD-1 downstream signaling and restores normal immune function by activating cytotoxic T lymphocytes and T cell-mediated immune responses against cancer cells. Currently, Camrelizumab is being investigated for treatment of advanced hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC) and Hodgkin lymphoma

Immunogen Sequence:Camrelizumab

Target Alternative Name:PDCD1, PD1, CD279, SLEB2, hPD-1, hPD-l, AiRuiKa™, SHR-1210, HR 301210, INCSHR 1210

Species Reactivities:/

Tag Line:Camrelizumab is a humanized IgG4 monoclonal antibody that blocks the binding of PD-1 to its ligands PD-L1 and PD-L2 and activates T-cell responses and inhibits the growth of cancer cells

Formulation:In PBS, pH 7.2

Purification: /

Application:In vivo studies

Positive Control:/

Application And Usages:In vivo studies

Handling:The antibody solution should be gently mixed before use.